These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 17642134)
1. Discontinuation of calcineurin inhibitors in heart transplant patients with end stage renal insufficiency as an alternative model of immunosuppression. Jerzy S; Wierzbicki K; Kapelak B; Konstanty J; Przybyłowski P; Wójcik S; Drwiła R; Wróbel K; Piatek J Przegl Lek; 2006; 63(12):1256-8. PubMed ID: 17642134 [TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
3. De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results. Meiser B; Buchholz S; Kaczmarek I Curr Opin Organ Transplant; 2011 Oct; 16(5):522-8. PubMed ID: 21836511 [TBL] [Abstract][Full Text] [Related]
4. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403 [TBL] [Abstract][Full Text] [Related]
8. Optimizing the immunosuppressive regimen in heart transplantation. Eisen H; Ross H J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807 [TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230 [TBL] [Abstract][Full Text] [Related]
10. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943 [TBL] [Abstract][Full Text] [Related]
11. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Sanchez V; Delgado JF; Morales JM; Tello R; Gómez MA; Escribano P; de la Cámara AG; de la Calzada CS Transplant Proc; 2004 Nov; 36(9):2823-5. PubMed ID: 15621159 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351 [TBL] [Abstract][Full Text] [Related]
13. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603 [TBL] [Abstract][Full Text] [Related]
14. Calcineurin inhibitor- and corticosteroid-free immunosuppression in pediatric heart transplant patients. Sierra CM; Tan R; Eguchi J; Bailey L; Chinnock RE Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27658616 [TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943 [TBL] [Abstract][Full Text] [Related]
16. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361 [TBL] [Abstract][Full Text] [Related]